Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

AZD1152 in Patients With Advanced Solid Malignancies
A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a 2-hour or 48-hour Intravenous Infusions in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  1/9/2017
Clinical Research Facility
mi
from
Boston, MA
AZD1152 in Patients With Advanced Solid Malignancies
A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a 2-hour or 48-hour Intravenous Infusions in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 1/9/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
AZD1152 in Patients With Advanced Solid Malignancies
A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a 2-hour or 48-hour Intravenous Infusions in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  1/9/2017
Clinical Research Facility
mi
from
New York, NY
AZD1152 in Patients With Advanced Solid Malignancies
A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a 2-hour or 48-hour Intravenous Infusions in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 1/9/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated:  1/9/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated: 1/9/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated:  1/9/2017
UCSF
mi
from
San Francisco, CA
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated: 1/9/2017
UCSF
mi
from
San Francisco, CA
Click here to add this to my saved trials
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated:  1/9/2017
Georgetown - Lombardi Cancer Center
mi
from
Washington,
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated: 1/9/2017
Georgetown - Lombardi Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated:  1/9/2017
Johns Hopkins University Medical Center
mi
from
Baltimore, MD
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated: 1/9/2017
Johns Hopkins University Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated:  1/9/2017
Massachusetts General Hospital
mi
from
Boston, MA
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated: 1/9/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated:  1/9/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated: 1/9/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated:  1/9/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated: 1/9/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated:  1/9/2017
North Shore Medical Center
mi
from
Peabody, MA
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated: 1/9/2017
North Shore Medical Center
mi
from
Peabody, MA
Click here to add this to my saved trials
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated:  1/9/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated: 1/9/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated:  1/9/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: Enrolling
Updated: 1/9/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer
Phase I Trial Of Adenoviral Vector Delivery Of The Human Interleukin-12 cDNA By Intratumoral Injection In Patients With Metastatic Colorectal Cancer To The Liver
Status: Enrolling
Updated:  1/10/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer
Phase I Trial Of Adenoviral Vector Delivery Of The Human Interleukin-12 cDNA By Intratumoral Injection In Patients With Metastatic Colorectal Cancer To The Liver
Status: Enrolling
Updated: 1/10/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined With FOLFOX Chemotherapy in Metastatic Colorectal Cancer (CA180048)
Status: Enrolling
Updated:  1/10/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined With FOLFOX Chemotherapy in Metastatic Colorectal Cancer (CA180048)
Status: Enrolling
Updated: 1/10/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Gene Therapy in Treating Women With Metastatic Breast Cancer
Phase I Trial of Adenoviral Vector Delivery of the Human Interleukin-12 cDNA by Intratumoral Injection in Patents With Metastatic Breast Cancer
Status: Enrolling
Updated:  1/10/2017
Icahn Medical Center at Mount Sinai
mi
from
New York, NY
Gene Therapy in Treating Women With Metastatic Breast Cancer
Phase I Trial of Adenoviral Vector Delivery of the Human Interleukin-12 cDNA by Intratumoral Injection in Patents With Metastatic Breast Cancer
Status: Enrolling
Updated: 1/10/2017
Icahn Medical Center at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Open-label, Single Arm, Safety and Tolerability Dose Escalation Study of VAL-083 in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  1/10/2017
University of California, San Francisco, Division of Neuro-Oncology
mi
from
San Francisco, CA
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Open-label, Single Arm, Safety and Tolerability Dose Escalation Study of VAL-083 in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 1/10/2017
University of California, San Francisco, Division of Neuro-Oncology
mi
from
San Francisco, CA
Click here to add this to my saved trials
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Open-label, Single Arm, Safety and Tolerability Dose Escalation Study of VAL-083 in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  1/10/2017
Sarah Cannon Research Institute
mi
from
Denver, CO
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Open-label, Single Arm, Safety and Tolerability Dose Escalation Study of VAL-083 in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 1/10/2017
Sarah Cannon Research Institute
mi
from
Denver, CO
Click here to add this to my saved trials
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Open-label, Single Arm, Safety and Tolerability Dose Escalation Study of VAL-083 in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  1/10/2017
Florida Cancer Specialists
mi
from
Sarasota, FL
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Open-label, Single Arm, Safety and Tolerability Dose Escalation Study of VAL-083 in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 1/10/2017
Florida Cancer Specialists
mi
from
Sarasota, FL
Click here to add this to my saved trials
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Open-label, Single Arm, Safety and Tolerability Dose Escalation Study of VAL-083 in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  1/10/2017
Sarah Cannon Research Institute
mi
from
Nashville, TN
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Open-label, Single Arm, Safety and Tolerability Dose Escalation Study of VAL-083 in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 1/10/2017
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Open-label, Single Arm, Safety and Tolerability Dose Escalation Study of VAL-083 in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  1/10/2017
The Mayo Clinic
mi
from
Rochester, MN
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Open-label, Single Arm, Safety and Tolerability Dose Escalation Study of VAL-083 in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 1/10/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Imaging Studies of Kidney Cancer Using 18F-VM4-037
PET Imaging Of Renal Cell Carcinoma With 18F-VM4-037: A Phase II Pilot Study For Detection Of Disease And Correlation With VHL Mutation Status
Status: Enrolling
Updated:  1/10/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Imaging Studies of Kidney Cancer Using 18F-VM4-037
PET Imaging Of Renal Cell Carcinoma With 18F-VM4-037: A Phase II Pilot Study For Detection Of Disease And Correlation With VHL Mutation Status
Status: Enrolling
Updated: 1/10/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery
A Randomized Three-arm Neoadjuvant and Adjuvant Feasibility and Toxicity Study of a GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine Administered Either Alone or in Combination With Either a Single Intravenous Dose or Daily Metronomic Oral Doses of Cyclophosphamide for the Treatment of Patients With Surgically Resected Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  1/11/2017
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery
A Randomized Three-arm Neoadjuvant and Adjuvant Feasibility and Toxicity Study of a GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine Administered Either Alone or in Combination With Either a Single Intravenous Dose or Daily Metronomic Oral Doses of Cyclophosphamide for the Treatment of Patients With Surgically Resected Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 1/11/2017
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients
Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients
Status: Enrolling
Updated:  1/11/2017
Washington University in St Louis
mi
from
St Louis, MO
Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients
Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients
Status: Enrolling
Updated: 1/11/2017
Washington University in St Louis
mi
from
St Louis, MO
Click here to add this to my saved trials
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
Phase I Trial of Everolimus, Gemcitabine, and Cisplatin for Patients With Solid Tumors Refractory to Standard Therapy
Status: Enrolling
Updated:  1/11/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
Phase I Trial of Everolimus, Gemcitabine, and Cisplatin for Patients With Solid Tumors Refractory to Standard Therapy
Status: Enrolling
Updated: 1/11/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
Phase I Trial of Everolimus, Gemcitabine, and Cisplatin for Patients With Solid Tumors Refractory to Standard Therapy
Status: Enrolling
Updated:  1/11/2017
Mayo Clinic Florida
mi
from
Jacksonville, FL
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
Phase I Trial of Everolimus, Gemcitabine, and Cisplatin for Patients With Solid Tumors Refractory to Standard Therapy
Status: Enrolling
Updated: 1/11/2017
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
Phase I Trial of Everolimus, Gemcitabine, and Cisplatin for Patients With Solid Tumors Refractory to Standard Therapy
Status: Enrolling
Updated:  1/11/2017
The Mayo Clinic
mi
from
Rochester, MN
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
Phase I Trial of Everolimus, Gemcitabine, and Cisplatin for Patients With Solid Tumors Refractory to Standard Therapy
Status: Enrolling
Updated: 1/11/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies
A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Subjects With Metastatic Non-Hematologic Malignancies
Status: Enrolling
Updated:  1/11/2017
HonorHealth Research Institute
mi
from
Scottsdale, AZ
Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies
A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Subjects With Metastatic Non-Hematologic Malignancies
Status: Enrolling
Updated: 1/11/2017
HonorHealth Research Institute
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies
A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Subjects With Metastatic Non-Hematologic Malignancies
Status: Enrolling
Updated:  1/11/2017
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies
A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Subjects With Metastatic Non-Hematologic Malignancies
Status: Enrolling
Updated: 1/11/2017
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies
A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Subjects With Metastatic Non-Hematologic Malignancies
Status: Enrolling
Updated:  1/11/2017
Florida Cancer Specialists
mi
from
Sarasota, FL
Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies
A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Subjects With Metastatic Non-Hematologic Malignancies
Status: Enrolling
Updated: 1/11/2017
Florida Cancer Specialists
mi
from
Sarasota, FL
Click here to add this to my saved trials
Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies
A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Subjects With Metastatic Non-Hematologic Malignancies
Status: Enrolling
Updated:  1/11/2017
Sarah Cannon Research Institute
mi
from
Nashville, TN
Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies
A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Subjects With Metastatic Non-Hematologic Malignancies
Status: Enrolling
Updated: 1/11/2017
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies
A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Subjects With Metastatic Non-Hematologic Malignancies
Status: Enrolling
Updated:  1/11/2017
Washington University School of Medicine, Division of Oncology
mi
from
St. Louis, MO
Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies
A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Subjects With Metastatic Non-Hematologic Malignancies
Status: Enrolling
Updated: 1/11/2017
Washington University School of Medicine, Division of Oncology
mi
from
St. Louis, MO
Click here to add this to my saved trials
Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases
Percutaneous US and CT-guided Cryoablation of Painful Metastases Involving Bone: A Feasibility Study
Status: Enrolling
Updated:  1/11/2017
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases
Percutaneous US and CT-guided Cryoablation of Painful Metastases Involving Bone: A Feasibility Study
Status: Enrolling
Updated: 1/11/2017
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases
Percutaneous US and CT-guided Cryoablation of Painful Metastases Involving Bone: A Feasibility Study
Status: Enrolling
Updated:  1/11/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases
Percutaneous US and CT-guided Cryoablation of Painful Metastases Involving Bone: A Feasibility Study
Status: Enrolling
Updated: 1/11/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases
Percutaneous US and CT-guided Cryoablation of Painful Metastases Involving Bone: A Feasibility Study
Status: Enrolling
Updated:  1/11/2017
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases
Percutaneous US and CT-guided Cryoablation of Painful Metastases Involving Bone: A Feasibility Study
Status: Enrolling
Updated: 1/11/2017
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases
Percutaneous US and CT-guided Cryoablation of Painful Metastases Involving Bone: A Feasibility Study
Status: Enrolling
Updated:  1/11/2017
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases
Percutaneous US and CT-guided Cryoablation of Painful Metastases Involving Bone: A Feasibility Study
Status: Enrolling
Updated: 1/11/2017
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases
Percutaneous US and CT-guided Cryoablation of Painful Metastases Involving Bone: A Feasibility Study
Status: Enrolling
Updated:  1/11/2017
NYU Cancer Institute at New York University Medical Center
mi
from
New York, NY
Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases
Percutaneous US and CT-guided Cryoablation of Painful Metastases Involving Bone: A Feasibility Study
Status: Enrolling
Updated: 1/11/2017
NYU Cancer Institute at New York University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases
Percutaneous US and CT-guided Cryoablation of Painful Metastases Involving Bone: A Feasibility Study
Status: Enrolling
Updated:  1/11/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases
Percutaneous US and CT-guided Cryoablation of Painful Metastases Involving Bone: A Feasibility Study
Status: Enrolling
Updated: 1/11/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases
Percutaneous US and CT-guided Cryoablation of Painful Metastases Involving Bone: A Feasibility Study
Status: Enrolling
Updated:  1/11/2017
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases
Percutaneous US and CT-guided Cryoablation of Painful Metastases Involving Bone: A Feasibility Study
Status: Enrolling
Updated: 1/11/2017
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases
Percutaneous US and CT-guided Cryoablation of Painful Metastases Involving Bone: A Feasibility Study
Status: Enrolling
Updated:  1/11/2017
Brown University School of Medicine
mi
from
Providence, RI
Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases
Percutaneous US and CT-guided Cryoablation of Painful Metastases Involving Bone: A Feasibility Study
Status: Enrolling
Updated: 1/11/2017
Brown University School of Medicine
mi
from
Providence, RI
Click here to add this to my saved trials
Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases
Percutaneous US and CT-guided Cryoablation of Painful Metastases Involving Bone: A Feasibility Study
Status: Enrolling
Updated:  1/11/2017
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases
Percutaneous US and CT-guided Cryoablation of Painful Metastases Involving Bone: A Feasibility Study
Status: Enrolling
Updated: 1/11/2017
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases
Percutaneous US and CT-guided Cryoablation of Painful Metastases Involving Bone: A Feasibility Study
Status: Enrolling
Updated:  1/11/2017
Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center
mi
from
Milwaukee, WI
Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases
Percutaneous US and CT-guided Cryoablation of Painful Metastases Involving Bone: A Feasibility Study
Status: Enrolling
Updated: 1/11/2017
Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
La Jolla, CA
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
New Haven, CT
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
New York, NY
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/12/2017
Research Site
mi
from
Parkville,
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/12/2017
Research Site
mi
from
Parkville,
Click here to add this to my saved trials
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  1/12/2017
University of Alabama at Birmingham, Comprehensive Cancer Center
mi
from
Birmingham, AL
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 1/12/2017
University of Alabama at Birmingham, Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  1/12/2017
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 1/12/2017
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  1/12/2017
Comprehensive Cancer Centers of the Desert
mi
from
Palm Springs, CA
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 1/12/2017
Comprehensive Cancer Centers of the Desert
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  1/12/2017
Loyola University Medical Center
mi
from
Maywood, IL
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 1/12/2017
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  1/12/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 1/12/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials